Home / Conditions / Arrhythmia Irregular Heart Rhythm
Arrhythmia Irregular Heart Rhythm: when insurers say no, reviewers often say yes
In 90 published external-review decisions involving arrhythmia irregular heart rhythm, independent physician reviewers overturned the insurer’s denial 48.9% of the time.
Published decisions
90
2001–2026
Overturned
48.9%
44 denials reversed
Most-fought treatments for arrhythmia irregular heart rhythm
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Heart Monitor | 15 | 20% |
| Surgery | 12 | 75% |
| Wearable Cardio Defib | 6 | 50% |
| Pacemaker Defib | 6 | 50% |
| Vein Ablation | 5 | 60% |
| Cardiac Rx | 4 | 50% |
| CT Scan | 3 | 0% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 50 | 46% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 39 | 51.3% |
Typical time to a decision
11 days
Most land between 5 and 21 days
Handled as urgent
51.1%
Expedited when a delay would cause harm
Recent direction
Falling
48.6% → 39.5% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for convergent ablation procedure. Convergent ablation is a hybrid method that combines minimally invasive endoscopic surgical epicardial ablation with endocardial catheter ablation, typically in two stages. It reduces the risks of esophageal and phrenic nerve injury and allows direct left atrium visualization while being less invasive than full surgical ablation. Few single-center studies and at least one randomized controlled trial suggest that this procedure provides greater and longer freedom from atrial fibrillation than traditional approaches.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a surgical endoscopic heart procedure (CPT 33266 - operative tissue ablation and extensive reconstruction of atria without cardiopulmonary bypass).Findings: Two of the three physician reviewers found the requested surgical endoscopic heart procedure (CPT 33266 - operative tissue ablation and extensive reconstruction of atria without cardiopulmonary bypass) is likely to be more beneficial for treatment of the patient’s medical condition than any available standard therapy. A hybrid procedure of minimally invasive surgery and combined electrophysiology (EP) mapping and ablation for atrial fibrillation may overcome the shortcomings of each technique individually.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a leadless pacemaker. Initial data for leadless pacemakers is promising, with low incidence of complications. However, the pooled data is from small observational studies with relatively limited follow-up periods of less than one year. To date, there have been no randomized controlled trials that have directly compared the safety and efficacy of leadless pacemakers versus transvenous pacing systems, the recommended first-line option for treatment. Furthermore, according to registry data, the life span of currently available leadless pacemakers is estimated to be approximately 10 years.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for computed tomography (CT) scan of the heart, without contrast, with qualitative evaluation of coronary calcium. Coronary artery calcium measured by cardiac CT can help provide an estimate of total coronary plaque burden and is an established tool for cardiovascular risk stratification and preventive therapy. Several guidelines have recommended the use of coronary artery calcium testing in shared decision making between the provider and patient. However, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines do not recommend coronary artery calcium for further evaluation of patients with ventricular tachycardia (Al-Khatib, et al.).
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for arrhythmia irregular heart rhythm was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.